A suboptimal dose intensity of adjuvant chemotherapy has been associated with a poor prognosis in patients with early-stage breast cancer. We investigated the relative dose intensity (RDI) of modern adjuvant chemotherapy regimens in patients aged ‡ 65 years. An RDI of ‡ 85% was achieved in 177 of 281 included patients (63%). Better supportive care of risk groups might further optimize the RDI. Introduction: Maintaining the relative dose intensity (RDI) of adjuvant chemotherapy at ! 85% has been associated with improved treatment outcomes in early-stage breast cancer (ESBC). Increasing evidence has suggested that patients aged ! 65 years can maintain the optimal RDI for standard chemotherapy regimens. The present study investigated the RDI of newer adjuvant chemotherapy regimens in this demographic. Patients and Methods: We retrospectively analyzed the data from 281 patients aged ! 65 years with a diagnosis of ESBC who had received adjuvant chemotherapy across 3 sites in Queensland, Australia from 2010 to 2015. The primary endpoint was the proportion of patients who had received an RDI of ! 85%. Results: The median age at diagnosis was 68 years (range, 65-85 years), with 36.3% aged > 70 years. The patient characteristics included tumor stage T3 or T4 in 17% and nodepositive disease in 60%. The common chemotherapy regimens included docetaxel/cyclophosphamide (23%), 5-fluorouracil/epirubicin/cyclophosphamide plus docetaxel or paclitaxel (17%); Adriamycin/cyclophosphamide/weekly paclitaxel (38%); and docetaxel/carboplatin/trastuzumab (11%). Primary (15%) and secondary (54%) granulocyte colonystimulating factor (G-CSF) was used. An RDI of ! 85% was achieved in 63% of the patients. Significant associations were noted between a reduced RDI and age ! 70 years (P < .001), Charlson comorbidity index ! 1 (P ¼ .043), initial dose reductions (P ¼ .01), secondary G-CSF use (P ¼ .45), hospital admission (P < .001), and febrile neutropenia (P ¼ .007). Treatment-related toxicities were the most common reason for noncompletion, with high rates of hospital admissions (46%) and febrile neutropenia (22%). Conclusion: Our findings suggest that patients aged ! 65 years with ESBC can maintain an optimal RDI with modern chemotherapy regimens. Appropriate geriatric assessment and the use of supportive measures such as G-CSF could better assist select groups to maintain an optimal dose intensity.
Introduction
Breast cancer is the leading cause of cancer and the second leading cause of cancer-related deaths among Australian women. Its incidence increases with age, with 59% of new diagnoses occurring in patients aged ! 65 years and a median age at presentation of 61 years. 1 Although the prognosis of primary breast cancer has improved significantly in recent decades, that trend has been heavily skewed toward younger patients. According to the breast cancer 1 mortality database compiled by the World Health Organization, women aged 50 and 69 years and those aged ! 70 years have experienced median improvements in mortality from 1989 to 2006 of 21% and 2%, respectively. 2 Recent studies have noted that a potential major reason for this comparatively poor prognosis among the elderly cohort is underusage of adjuvant chemotherapy in this patient group. 3, 4 Older patients have been more likely to receive dose reductions and delays, reducing the overall relative dose intensity (RDI) of their treatment. 5 Dose intensity refers to the measure of chemotherapy drug delivered per unit time (ie, mg/m 2 /wk), and the RDI is defined as the received dose intensity relative to the reference dose intensity. The RDI is an important prognostic factor that reflects the degree of adherence to the recommended chemotherapy regimen and, by extension, the safety and tolerability of these treatments. The maintenance of the RDI at greater than a minimum optimal threshold of 85% has been shown to correlate with increased rates of disease-free survival and overall survival. [6] [7] [8] The reported data have suggested that a key cause of this age-based discrepancy in treatment was the historical consensus that adjuvant chemotherapy treatments are poorly tolerated by older patients compared with their younger counterparts. Several older studies reported significantly greater rates of toxicity and mortality associated with first-and second-generation adjuvant regimens among elderly breast cancer patients, leading to caution when prescribing chemotherapy in this demographic. 5, [8] [9] [10] However, an increasing body of evidence has suggested that select older patients will tolerate a range of adjuvant chemotherapy regimens better than previously thought and will be capable of maintaining an optimal dose intensity. [11] [12] [13] [14] The primary aim of the present study was to assess whether patients aged ! 65 years who received adjuvant chemotherapy for early-stage breast cancer (ESBC) could maintain an RDI of ! 85%.
Materials and Methods

Subjects and Data Collection
A retrospective analysis was conducted of all patients aged ! 65 years who had undergone surgical resection for ESBC and received adjuvant chemotherapy across 3 sites in Queensland, Australia from 2010 to 2015. Patients receiving palliative intent treatment were excluded from the present study. The primary outcome measure was to assess the proportion of patients reaching a RDI of ! 85%. The secondary outcome measures age, body mass index (BMI), Charlson comorbidity index, chemotherapy protocol, the use of granulocyte colony-stimulating factor (G-CSF), and toxicity data and were assessed to determine their effect on the dose intensity. RDI was analyzed against disease recurrence and patient mortality. The human research ethics committee granted low-risk ethical approval (approval no. HREC/15/QRBW/320) for the present study, with the need for individual patient consent waived.
Dose Intensity
The RDI was calculated as the ratio of the actual dose intensity to the standard dose intensity. To calculate the standard dose intensity (mg/m 2 /wk), the total chemotherapy dose standard to each protocol was divided by the standard duration of that protocol, including all planned cycles. To calculate the actual dose intensity, the total chemotherapy dose received by each patient during their treatment 
Statistical Analysis
The patient characteristics and clinical and pathologic factors were summarized using frequencies and percentages for the categorical variables and median and interquartile range for continuous variables. The 
Results
Patient Characteristics
A retrospective review yielded 281 eligible patients whose clinical and pathologic characteristics are listed in Compared with their older counterparts, patients aged 65 to 69 years had significantly greater rates of T1-T2 disease (67%) compared with patients aged ! 70 years (33%), greater rates of HER 2 negativity (68% vs. 32%), and greater rates of wide local excision (78% vs. 22%). Older patients received equivalent rates of AC-wT (48% for patients aged ! 70 years vs. 52% for patients aged 65 to 69 years) but significantly greater rates of weekly paclitaxel (75% vs. 25%) and significantly lower rates of TC (20% vs. 80%), TAC (12% vs. 88%), and FEC-D/T (29% vs. 71%). No significant difference was found among the other parameters, including Charlson comorbidity index, Eastern Cooperative Oncology Group performance status, TNM stage, hormone receptor status, number of admissions, febrile neutropenia rates, or the use of G-CSF.
Tolerability and Feasibility of Chemotherapy
A total of 177 patients (63%) achieved an RDI of ! 85%, with 121 (43%) maintaining an RDI of 100%. An RDI of < 65 occurred in 49 patients (17%). An initial dose reduction or capping of the dose was required for 29 patients (10%). Dose reductions were required for 64 patients (23%), dose delays for 58 (21%), and dose delays > 2 weeks for 17 patients (6%). Of the 281 patients, 178 (63%) completed all prescribed chemotherapy cycles. The most common reasons for noncompletion were treatment-related toxicities, including febrile neutropenia in 62 (22%) and peripheral neuropathy in 145 (52%). Primary G-CSF was used in 41 patients (15%), with a requirement for secondary G-CSF in 148 patients (54%). A high rate of primary G-CSF prophylaxis was used with the TAC (75%) and FEC-D (58%) chemotherapy regimens. Febrile neutropenia occurred most often with the TC (34%), followed by the TCH (30%) chemotherapy protocol in those patients who did not receive primary prophylaxis (Table 2) . Of the 281 patients, 129 (46%) experienced ! 1 admissions, with 49 (17%) experiencing ! 2 admissions. Treatment-related toxicities and the use of G-CSF were not significantly different between the patients aged 65 to 69 years and those aged ! 70 years. 
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Factors Associated With RDI A significant association was found between a reduced RDI and age > 70 years (P < .001), Charlson comorbidity index of ! 1 (P ¼ .043), initial dose reduction (P ¼ .001), admission to the hospital (P < .001), febrile neutropenia rate (P ¼ .007), and requirement for secondary G-CSF use (P ¼ .045). No significant association was noted between the RDI and primary G-CSF use, BMI, or individual chemotherapy protocol (Table 3) .
The results of the univariable and multivariable logistic regression analyses of the relationship between RDI and age group and Charlson comorbidity index are presented in Table 4 . The univariable analyses demonstrated that the Charlson comorbidity index and age were significantly associated with the RDI (P ¼ .044 and P < .001, respectively). The odds of achieving an optimum dose intensity was 75% lower (odds ratio, 0.25; 95% confidence interval, 0.15-0.41) for patients aged ! 70 years compared with the younger age group and 33% lower (odds ratio, 0.67; 95% confidence interval, 0.46-0.97) for patients with a higher Charlson comorbidity index (> 1) compared with those with a Charlson comorbidity index of 0. The effect of age group was further examined by adjusting for the Charlson comorbidity index on multivariable analysis. The effect of age group remained statistically significant, with no considerable changes in the odds ratios.
Clinical Outcomes
The median follow-up length was 43 months (range, 6-117 months). No statistically significant association was found between the RDI and recurrence or overall mortality, with 37 events of breast cancer recurrence and 32 deaths (Table 5 ).
Discussion
Maintenance of RDI
The results of the present study have demonstrated that a significant proportion of selected older patients with ESBC are capable of maintaining an optimal dose intensity for adjuvant chemotherapy. An RDI of ! 85% was achieved by 63% of the cohort, with 43% of patients maintaining an RDI of 100%. We compared these findings with those from several recent studies (Table 6 ). In their retrospective review, Raza et al 12 found that a comparable 65% of patients aged ! 65 years maintained an RDI of ! 85% for adjuvant chemotherapy. However, studies by Lyman et al, 11 Oladipo et al, 13 and Ngamphaiboon et al 15 showed greater rates of optimal RDI among elderly patients: 75%, 78%, and 81%, respectively. Several key methodologic discrepancies were present that might account for these differences in outcomes. A large proportion of our cohort was treated with third-generation anthracycline-and taxane-based chemotherapy regimens such as FEC-D, FEC-T, and TAC. In contrast, the other studies relied largely on first-and second-generation treatments. The only other use of newer protocols was by Raza et al 12 and Oladipo et al. 13 In their studies, 22% and 2% of patients, respectively, received FEC-D.
12,13
Another key difference is that several of these studies used considerably greater rates of primary prophylactic G-CSF to minimize the rates of treatment-related febrile neutropenia and thus improve the dose intensity. Although the present study failed to find an association between primary G-CSF use and RDI, it is important to note that the rate of primary G-CSF use among our cohort was too low for firm conclusions. However, the use of secondary G-CSF did significantly improve the dose intensity. In the patient cohorts investigated by Ngamphaiboon et al 15 and Lyman et al, 11 100%
and 81% of the patients received primary G-CSF prophylaxis, respectively. In contrast, only 15% of our patients received this treatment. This approach has been widely supported in recent data, and current European and American consensus panels have recommended consideration of G-CSF use for patients undergoing Ngamphaiboon et al 15 were primarily investigating elderly patients, who only constituted 22% (n ¼ 37) and 14% (n ¼ 24) of the participants, respectively, the statistical power of their conclusions regarding patients aged ! 65 years is limited compared with our large retrospective cohort.
Factors Affecting RDI
Our results implicate age as an independent risk factor for reduced dose intensity; patients aged ! 70 years were significantly less likely to maintain an optimal dose intensity than those who were aged 65 to 69 years. When attempting to correlate our findings with other reported data, we noted a lack of research involving elderly cancer patients, especially those aged > 70 years, with some studies actively excluding this age bracket, and the studies that do exist have yielded mixed results. 13, 19 Lyman et al 11 found that increasing age was not associated with the risk of a suboptimal RDI.
Also, although Oladipo et al 13 noted that fewer patients aged 70
years had maintained an RDI of ! 85%, the difference was not statistically significant. In contrast, Shayne et al 20 investigated the dose intensity for cancer patients aged ! 70 years and found that increasing age was associated with a lower RDI (P ¼ .03), most markedly in the age bracket of ! 80 years. Because their cohort included 976 patients, the statistical power of these results is greater than that of the previously cited studies; however, their results are not directly comparable to ours because only 13% of their patients had breast cancer and only 52% were treated with curative intent. 20 Other studies have implicated age ! 70 years as a significant predictor of reduced RDI of chemotherapy, but none had a specific focus on ESBC. 21, 22 In our study, significant variation was present in the chemotherapy protocols prescribed to these 2 age groups.
Older patients received lower rates of TC, FEC-D, and TAC chemotherapy regimens and greater rates of weekly paclitaxel alone, which was deemed more tolerable. Older patients with HER2 þ breast cancer might have continued to receive anti-HER2 agent on stopping chemotherapy as an alternative, more tolerable treatment option.
The Charlson comorbidity index scores were comparable between the 2 age groups, which contradicts the greater rates of comorbidity among elderly patients in the reported data. 23 This might simply reflect a selection bias of patients seen in the medical oncology department for consideration of adjuvant therapies, such that patients with comorbidities are less likely to be referred and ultimately treated. The Charlson comorbidity index was shown to have a significant effect on RDI maintenance, albeit to a lesser degree than age, in keeping with previous research of this patient demographic. 24 One potential cause for this trend is that a coexisting major illness is known to adversely affect adherence to institutional therapeutic guidelines. 4, 25 However, as stated previously, the differences we found in chemotherapy regimen prescription between the age groups was not accounted for by comorbidity status. Obesity is another patient-related factor that has been independently implicated in causing reductions of RDI; however, this finding was not replicated among our cohort. 26, 27 Although a greater proportion of patients with a BMI > 24.9 kg/m 2 failed to reach an optimal dose intensity, this association remained statistically insignificant. Although a significant difference was found in the choice of chemotherapy and maintaining RDI, a selection bias was likely present, in particular, related to comorbidities and performance status. For example, clinicians are more inclined to choose chemotherapy for HER2 þ ESBC, so that the patients can receive concurrent trastuzumab. Therefore, patients might be included for chemotherapy who otherwise would have received endocrine treatment without chemotherapy. This might explain the reduced RDI < 85% with TCH (53%) and weekly paclitaxel (67%). In general, it has been shown that relative to first-generation adjuvant therapies, second-generation regimens are more efficacious in the treatment of ESBC and, importantly, are well tolerated in older patients. 28 Although research is comparatively lacking into the tolerability of third-generation adjuvant cytotoxic regimens in this demographic, some evidence has suggested that newer, dose-intense anthracycline-based regimens are equally as effective across age 
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Clinical Breast Cancer October 2018 -e1185 groups, are significantly more effective than first-generation regimens, and are tolerated in healthy elderly patients in the setting of primary G-CSF prophylaxis. 5, 10 Raza et al 12 recorded greater rates of optimal RDI with AC-wT, FEC-D, and FEC-100 (96%, 95%, and 71%, respectively); however, statistical power was also a limiting factor in their study. As expected, hospital admissions during treatment were associated with significant reductions in RDI. Most of the reductions in RDI occurred after the first cycle and were thus attributable to unplanned factors such as treatment-related toxicity. The most pronounced treatment-related toxicity experienced by our cohort was febrile neutropenia (22%). The RDI significantly improved with secondary G-CSF use. The use of primary G-CSF prophylaxis could ameliorate the risk of febrile neutropenia in this population and further improve the RDI.
Prognostic Significance of RDI
At the last follow-up point, few patients had developed recurrence or died in our cohort, although the follow-up period was short. As such, we did not find a significant association between RDI and cancer recurrence, all-cause mortality, or cancer-specific mortality. Although some studies failed to report worse outcomes associated with reductions in RDI, the weight of research supports the prognostic significance of the dose intensity. 6, 7, 29, 30 The ESBC survival rates associated with a dose intensity of < 65% are comparable to those of untreated control groups, and a dose reduction of 20% has been show to halve the rates of cure in this demographic. 31 
Study Limitations
The present study had a number of limitations, chief among them was the relatively small sample size, which resulted in insufficient statistical power to analyze the effect of the chemotherapy regimen on the RDI. In addition, the brief follow-up period did not allow for conclusive assessment of the prognostic significance of the RDI. Other sources of inaccuracy included the broad manner in which the toxicity data were recorded as per the Common Terminology Criteria for Adverse Events, version 1.1, reference, and the difficulty in accessing the records for noneQueensland Health hospital admissions. Finally, a selection bias must also be considered because poor health and performance status likely prevented many older, less fit patients from being referred for consideration of adjuvant chemotherapy. Also, in the event of a successful referral, these patients might have been less likely to receive treatment than their younger counterparts. As such, the feasibility and tolerability data are likely skewed by the resulting younger, healthier cohort. However, this is conjecture because the total numbers of patients considered for referral and treatment were not recorded.
Conclusion
Our results showed that patients aged ! 65 years with ESBC can maintain an optimal RDI through a range of newer adjuvant chemotherapy protocols. However, the tolerance of these regimens remains suboptimal, with high rates of treatment-related toxicities necessitating admission and treatment delay. Given its prognostic importance, it is essential to minimize reductions in the RDI through the early and widespread use of supportive measures, including secondary G-CSF prophylaxis, especially in the at-risk populations identified in the present study, as well as through the effective management of treatment-related toxicities. The routine use of a comprehensive geriatric assessment in older patients might have a role to play in the latter, although more research is required in this area. 32 A paucity of clinical research in elderly cancer patients has continued, necessitating larger scale investigation into the factors influencing the RDI in this demographic, especially regarding the newer chemotherapy regimens. 
Clinical Practice Points
Maintaining a greater dose intensity (! 85%) with newer chemotherapy regimens in patients aged ! 65 years with breast cancer is unknown. Our results have shown that patients with early-stage breast cancer can maintain an optimal RDI through a range of newer adjuvant chemotherapy protocols; however, the tolerance of these regimens has remained suboptimal, with high rates of treatment-related toxicities. The reductions in RDI can be minimized through the early and widespread use of supportive measures, including G-CSF prophylaxis and effective management of treatment-related toxicities.
The routine use of comprehensive geriatric assessment in older patients might better identify patients requiring these supportive measures.
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